Citigroup’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-33,672
| Closed | -$3.27M | – | 7912 |
|
|
2019
Q3 | $3.27M | Sell |
33,672
-105,346
| -76% | -$10.5M | ﹤0.01% | 2336 |
|
|
2019
Q2 | $14.2M | Sell |
139,018
-82,396
| -37% | -$8.89M | 0.01% | 1150 |
|
|
2019
Q1 | $25.2M | Buy |
221,414
+137,183
| +163% | +$10.1M | 0.02% | 711 |
|
|
2018
Q4 | $3.3M | Buy |
84,231
+4,630
| +6% | +$201K | ﹤0.01% | 2211 |
|
|
2018
Q3 | $4.34M | Buy |
79,601
+34,038
| +75% | +$2.33M | ﹤0.01% | 1993 |
|
|
2018
Q2 | $3.77M | Sell |
45,563
-12,815
| -22% | -$989K | ﹤0.01% | 2105 |
|
|
2018
Q1 | $3.89M | Sell |
58,378
-5,321
| -8% | -$307K | ﹤0.01% | 1997 |
|
|
2017
Q4 | $3.28M | Buy |
63,699
+27,307
| +75% | +$1.96M | ﹤0.01% | 2221 |
|
|
2017
Q3 | $3.25M | Sell |
36,392
-37,559
| -51% | -$2.85M | ﹤0.01% | 2158 |
|
|
2017
Q2 | $4.42M | Buy |
73,951
+47,347
| +178% | +$2.65M | ﹤0.01% | 1801 |
|
|
2017
Q1 | $1.42M | Sell |
26,604
-73,133
| -73% | -$4.34M | ﹤0.01% | 2837 |
|
|
2016
Q4 | $4.98M | Buy |
99,737
+88,420
| +781% | +$4.74M | ﹤0.01% | 1841 |
|
|
2016
Q3 | $680K | Buy |
11,317
+3,617
| +47% | +$208K | ﹤0.01% | 3612 |
|
|
2016
Q2 | $394K | Sell |
7,700
-6,273
| -45% | -$268K | ﹤0.01% | 3894 |
|
|
2016
Q1 | $413K | Buy |
13,973
+4,820
| +53% | +$152K | ﹤0.01% | 4345 |
|
|
2015
Q4 | $415K | Sell |
9,153
-9,525
| -51% | -$499K | ﹤0.01% | 4049 |
|
|
2015
Q3 | $779K | Buy |
18,678
+18,001
| +2,659% | +$939K | ﹤0.01% | 3329 |
|
|
2015
Q2 | $40K | Sell |
677
-1,958
| -74% | -$129K | ﹤0.01% | 5689 |
|
|
2015
Q1 | $205K | Buy |
+2,635
| New | +$152K | ﹤0.01% | 4502 |
|
Citigroup's ONCE Position: Q4 2019 in Review
Citigroup sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q4 2019, closing a stake of 33,672 shares — an estimated $3.27M sold.
Citigroup first reported a position in ONCE in Q1 2015 and held it in 19 quarters. The position peaked at $25.2M in Q1 2019. 0 funds tracked by Wall St. Rank hold ONCE as of Q4 2019.
- Citigroup reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
- Citigroup sold 33,672 Spark Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $3.27M.
- Citigroup first reported a position in Spark Therapeutics, Inc. Common Stock in Q1 2015 and held it in 19 quarters.
- Citigroup's Spark Therapeutics, Inc. Common Stock position peaked at $25.2M in Q1 2019.
- 0 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q4 2019.
Based on Citigroup's 13F filing for Q4 2019, filed 12 Feb 2020.